ReviewSignal transduction and targeted therapy2023
Mpox (formerly monkeypox): pathogenesis, prevention, and treatment.
Review in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Epidemiological characteristics of monkeypox virus infection: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Exploring Green-Synthesized Silver Nanoparticles in Neurodegeneration: a Systematic Review of Cholinesterase Enzyme Interactions.Molecular neurobiology · 2026Pooled it
- Hospitalization rate and patterns of clinical reasons among Mpox-confirmed cases: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Multi-organ clinical manifestations of Mpox: an umbrella review of systematic reviews.BMC infectious diseases · 2024Pooled it
- Epidemiology and phylogenomic characterization of the Clade IIb C.1 Mpox outbreak in Phnom Penh, Cambodia (2023-2024).Emerging microbes & infections · 2026Article
- Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.Emerging microbes & infections · 2026Article
- Biphasic phenotypic adaptation of sheeppox virus consequent to serial passaging in heterologous host cell type.Archives of virology · 2026Article
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Structure prediction and drug screening targeting monkeypox virus polymerase and surface proteins.Journal of computer-aided molecular design · 2026Article
- Monkeypox-Associated Genital Necrosis in an Immunocompromised Patient: Case Report and Literature Review of Genital Mpox Reconstruction.Archives of plastic surgery · 2026Article
- Sulfur valence normalization to expand quantitative peptide selection in protein metrology.Analytical and bioanalytical chemistry · 2026Article
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Adaptive mutations at lysine residues of PRRSV-2 nsp12 enable evasion of host proteasomal degradation to promote subgenomic RNA synthesis.Journal of virology · 2026Article
- Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection.RSC pharmaceutics · 2026Article
- Rational design of anticancer multidrug nanosystems and their adaptation for glioblastoma treatment.Drug delivery and translational research · 2026Review
- Cellular miR-24-3p inhibits vaccinia virus replication by targeting kinesin-like protein KIF21B.Biosafety and health · 2026Article
- 3-Hydroxypyrimidine-2,4-dione derivatives as monkeypox virus resolvase (Mpr) inhibitors.RSC medicinal chemistry · 2026Article
- Durable but impaired humoral and cellular immune responses against monkeypox virus in people with HIV over 18 months.Journal of translational medicine · 2026Article
- CircRNA based bi-antigen vaccines against mpox virus induce potent and durable cross-protection in mice.Molecular biomedicine · 2026Article
- Therapeutic Innovations for Monkeypox Inhibition.International journal of molecular sciences · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.